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MiR-27aHypoxia stimulates angiogenesis under a variety of pathological conditions, including malignant tumors by
inducing expression of angiogenic factors such as VEGFA. Surprisingly, here we report signiﬁcant association
between down-regulation of a new angiogenic factor AGGF1 and high-grade urothelial carcinoma. The propor-
tion of strong AGGF1 expression cases was signiﬁcantly lower in the high-grade urothelial carcinoma group
than that in the low-grade urothelial carcinoma group (P=1.40 × 10−5) or than that in the normal urothelium
tissue group (P=2.11 × 10−4). We hypothesized that tumor hypoxiawas responsible for differential expression
of the AGGF1protein in low- and high-grade urothelial carcinomas, and therefore investigated themolecular reg-
ulatory mechanism for AGGF1 expression under hypoxia. Under hypoxic conditions, AGGF1 protein levels
declined without any change in mRNA levels and protein stability. Hypoxia-induced down-regulation of
AGGF1 was mediated by miR-27a. Overexpression of miR-27a suppressed AGGF1 expression through transla-
tional inhibition, but not by RNA degradation.Moreover, the hypoxia-induced decrease of AGGF1 expression dis-
appeared after miR-27a expression was inhibited. Furthermore, down-regulation of AGGF1 reduced hypoxia-
induced apoptosis in cancer cells. Taken together, the results of this study indicate that (1) hypoxia down-
regulates expression of the AGGF1 protein, but not AGGF1 mRNA, by inducing expression of miR-27a; (2)
Down-regulation of AGGF1 had an apparent protective role for cancer cells under hypoxia; (3) Down-
regulation of the AGGF1 protein confers a signiﬁcant risk of high-grade human urothelial bladder carcinoma.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Hypoxia occurs during a range of diverse physiological and
pathophysiological states, including development, cancer, and chronic
inﬂammation [1]. Most solid tumors contain substantial hypoxic
regions, and the extent and severity of the region correlate with poor
prognosis in patients [2]. Moreover, hypoxic cancer cells usually show
resistance to chemotherapy and radiotherapy, which are also associated
with poor clinical prognosis [3]. Hypoxic conditions trigger coordinated
regulation of many genes, including those involved in increased angio-
genesis, up-regulation of glycolytic enzymes and genetic instability [4].
Studies of the mechanisms underlying the regulation of such genes
have emphasized the dominant role of the hypoxia-inducible factor
(HIF) transcriptional system [5]. Recently, another mechanism of geneResearch, Huazhong University
na.
ccf.org (Q.K. Wang).
ights reserved.regulation mediated by microRNAs (miRNAs) in hypoxia was identiﬁed
[5–7]. MiRNAs are small non-coding RNAs that repress target gene
expression through RNA degradation and/or translational inhibition
[8–10]. MiRNAs have been shown to affect fundamental cellular process-
es, including cell cycle regulation, proliferation, and apoptosis [11,12].
AGGF1 is a newly identiﬁed angiogenic factor which is highly
expressed in endothelial cells and promotes angiogenesis as potently as
VEGF in a chick embryo angiogenesis assay [13]. Increased AGGF1 expres-
sion is associated with vascular disease Klippel–Trenaunay syndrome
[13,14]. Our group has demonstrated that AGGF1 overexpression in
zebraﬁsh embryos activates the AKT signaling pathway to induce the
speciﬁcation of vein identity and angiogenesis [15]. More recently, we
have found that AGGF1 is themaster regulatory gene that drives differen-
tiation of the mesodermal cells to multipotential hemangioblasts [16].
Increased AGGF1 expression increases angiogenesis and blood ﬂow and
improves limb functions in a mouse hindlimb ischemia model of periph-
eral artery disease [17]. Tumor growth and expansion require angiogene-
sis, whichmay involve hypoxia-induced expression of angiogenic factors.
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and metastasis, however, remains unknown.
Bladder carcinoma is the fourthmost commonmalignancy inmen in
theUnited States. Urothelial carcinoma is themost commonhistological
subtype of bladder cancer and accounts for 90%–95% of cases, while
squamous cell carcinoma represents only 5% of cases [18]. In 2013, it
was estimated that 72,570 new patients would be diagnosedwith blad-
der cancer, and 15,210were projected to die from the disease [19]. Most
cases of urothelial cancer are papillary tumors that have been classiﬁed
into low-grade and high-grade papillary urothelial carcinomas. The
latter is biologically more aggressive and carries a high probability of
progression into muscle-invasive carcinoma and cancer-speciﬁc
mortality [20]. Early detection and a deeper molecular understanding
of urothelial bladder cancer are needed to improve diagnosis and treat-
ment [21]. Many markers were implicated in identiﬁcation of patients
who may have an aggressive form of urothelial carcinoma and also in
affecting outcome after treatment. But until now none of the current
prognostic molecular markers are sufﬁciently validated [22].
In the present study, we showed that high-grade bladder carcinoma
was associated signiﬁcantlywith down-regulation of theAGGF1 protein
as compared to normal bladder tissues and low-grade bladder carcino-
ma. To investigate the molecular mechanisms of down-regulation of
AGGF1 expression in high-grade bladder carcinoma, we hypothesized
that hypoxia regulates AGGF1 expression. Our study showed that
hypoxia induced a dramatic decrease in the expression of AGGF1 in
different human cancer cells, whereas expression of control proteins
HIF1α and VEGF-A (markers of hypoxia) increased as expected. The
hypoxia-induced decrease in AGGF1 expression only occurred at the
protein level instead of transcriptional suppression, and was mediated
by miR-27a.2. Materials and methods
2.1. Evaluation of AGGF1 expression by immunohistochemistry in human
bladder tissues
Urothelial carcinoma and normal urothelial tissue samples were
collected from 59 patients undergoing surgery at the Cleveland Clinic.
The World Health Organization classiﬁcation of bladder tumors
was used to assess the histologic grading of urothelial carcinomas. The
grading of tumors was evaluated by at least two pathologists and sur-
geons. Thirty tumors were classiﬁed as low-grade urothelial carcinomas
(LGUCC) and 22 were high-grade urothelial carcinomas (HGUCC).
Seven normal non-neoplastic urothelial tissue samples were obtained
from patients with non-neoplastic bladder diseases. The thirty low
grade and 22 high grade urothelial carcinomas were used to construct
the tissue microarray (TMA). The thirty low grade tumors were all trans-
urethral resection specimens. Twentynine of themwere pTa andone case
was pT1. For 22high grade tumors, 15were radical cystectomy specimens
and 7 were transurethral resections. The pT stage was Ta in 3, T1 in 1, T2
in 6 and T3 in 12. The pN stage was Nx in 7, N0 in 11, N1 in 3 and N2 in 4.
All 59 cases were retrieved from the surgical pathology ﬁles and re-
reviewed to conﬁrm the original diagnoses by independent patholo-
gists. One or more tissue representative blocks were used to construct
a TMA. For each case, three 1.5-mm cores were taken to construct the
TMA. This TMA was then sectioned into 4-μm sections. Hematoxylin-
eosin (H&E) stainingwas performed to verify the histological diagnoses.
The sections were used for immunostaining analysis using an anti-
AGGF1 antibody as described [13]. Brieﬂy, 4-μm tissue sections were
antigen-retrieved in 0.1 M citrate buffer, pH 6.0, in a pressure steamer
for 15min. The slideswere then incubated sequentially with the primary
antibody, a biotinylated secondary antibody, avidin-peroxidase complex
(Ventana, Tucson, AZ) and chromogenic substrate diaminobenzidine.
The immunostainingwas performed on a Ventana Benchmark automatic
stainer (Ventana, Tucson, AZ).In the follow-up conﬁrmation study, urothelial carcinoma tissue sam-
ples along with normal adjacent urothelial tissue samples were collected
from 4 patients undergoing surgery at Huazhong University of Science
and Technology (B35, B76, B84 and B85). In B35, the tumor invaded the
full thickness of the bladder and was staged as pT3N0M0. In B76, the
tumor invaded the inner muscularis propria with left iliac lymph node
metastasis. B84 represented an inverted papilloma. In B85, the tumor
was low grade and was staged as T2N2M0. However, it invaded lamina
propria with right iliac lymph node metastasis. It should be noted that it
is rare for a lowgradebladder cancer tometastasize, thus a caution should
be taken with interpretation of the stage of the B85 tumor.
Immunohistochemistry analysiswas used for assessing the expression
level of the AGGF1 protein in TMAs with a polyclonal anti-AGGF1 anti-
body reportedpreviously [13] and in the conﬁrmation studywith another
polyclonal anti-AGGF1 antibody (Proteintech, Wuhan, Hubei, China).
Normal urothelial cells strongly expressed AGGF1, but stromal cells did
not (Fig. 1A). Therefore, urothelial carcinomas with an AGGF1 expression
level similar to normal urothelial cells were graded as “strongly positive”,
while those with an expression level intermediate between normal
urothelial cells and stromal cells were graded as “weakly positive”
(Fig. 1A).
This study was approved by Institutional Review Boards on Human
Subject Research at Cleveland Clinic and Huazhong University of Science
and Technology. The informed written consent was obtained from each
patient.2.2. Cell culture
The human bladder cancer cell line (J82), human colon cancer cell line
(HCT116), human cervical cancer cell line (HeLa), human non-small cell
lung carcinoma cell line (H1299) and human embryonic kidney cell line
(HEK293) were from the American Type Culture Collection (ATCC,
Rockville, MD, USA). J82 cells were maintained in the Minimal Essential
Mediumwith Earle's (MEM/EBSS, Hyclone, Logan, UT, USA) supplement-
ed with 10% fetal bovine serum (FBS, Hyclone). Other cell lines were
maintained in Dulbecco's modiﬁed Eagle's medium (DMEM, Hyclone)
supplemented with 10% FBS (Hyclone). The cells were cultured at 37 °C
in a humidiﬁed incubator with 5% CO2.2.3. Cell transfection
For plasmid DNA, cells were transfected using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's
instructions.
For studies ofmiR-27a, cells were transiently transfectedwith 100 nM
of a miR-27a mimics or an inhibitor (Ribobio, Guangzhou, Guangdong,
China) with Lipofectamine 2000 according to themanufacturer's instruc-
tions. Forty-eight hours after transfection, cells were harvested and lysed
for preparation of protein extracts.
For RNAi, cells were transfected with 100 nM siRNA using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer's instructions.2.4. Hypoxic exposure conditions
The standard hypoxic exposure condition was 3% O2 (or 1% O2 as
indicated in the text), 5% CO2, and 92% N2 (or 94% N2) in a Hypoxia
Chamber (HF100 Incubator, Heal Force Bio-Meditech Holdings Limited,
Shanghai, China). At the start of each experiment, the culture media
were replaced with pre-equilibrated normoxic or hypoxic media. Cells
were cultured in 6-well plates and exposed to hypoxia for a period of
2, 6, 24 or 48 h. Hypoxic conditions were also mimicked using a
hypoxia-mimetic agent, cobalt (II) chloride (CoCl2, Sigma-Aldrich,
St. Louis, MO, USA) [23–25].
Fig. 1. Differential expression of AGGF1 in normal urothelium and different histological grades of urothelial carcinomas. (A) Immunostaining analysis of AGGF1 expression in
representative samples: no AGGF1 expression (negative−), weak AGGF1 expression (weak +), and strong AGGF1 expression (strong +). (B) Normal urothelium and a low-grade
urothelial carcinoma exhibited strong immunostaining for AGGF1 protein. In contrast, negative or weak AGGF1 immunoreactivity was detected in a high-grade urothelial carcinoma.
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We used three programs and related databases, TargetScan 5.2 [26],
PicTar [27] and MiRanda [28], to predict potential binding sites of
miRNAs to the 3′-untranslated region (3′-UTR) of AGGF1.
2.6. Plasmids and siRNAs
The 3′-UTR of AGGF1 with a putative miR-27a binding site was
ampliﬁed by a polymerase chain reaction (PCR) using human genomic
DNA as the template. The PCR product was digested with Spe I and
Hind III, and sub-cloned into the pMIR-REPORT luciferase plasmid
(Applied Biosystems, Foster City, CA, USA), resulting in pMIR-AGGF1-
3′-UTR-wt. Primers used for constructing pMIR-AGGF1-3′-UTR-wt
were 5′-GGACTAGTTTGCGAAAACATGGGTAGTG-3′ (forward) and 5′-
CCCAAGCTTTGCCTGCAATGGTCTTTATC-3′ (reverse).
The miR-27a binding site was mutated in pMIR-AGGF1-3′-UTR-wt
using PCR-based site-directed mutagenesis and the construct was
referred to as pMIR-AGGF1-3′-UTR-mut. The seed region of the predicted
miR-27a site (CUGUGAA) was mutated to CCUAUAA.
Two siRNAs targeting the AGGF1 mRNA sequence were chemically
synthesized by RiboBio. Silencer scrambled negative control siRNA
(siNC) having no signiﬁcant homology to any known gene sequence
from humans was also purchased from RiboBio. The sequences of
siRNA duplexes were as follows: 5′- GUCGGAAGAUGUUGGAGAAdTdT-
3′ (sense) for siAGGF1-B and 5′- GCUGUAAACCCUGCUACAAdTdT-
3′(sense) for siAGGF1-C.2.7. Luciferase assays
For luciferase assays, HEK 293 cells were plated in a 96-well plate for
24 h before transfection. Cells were co-transfected with 50 ng of either
the pMIR-AGGF1-3′-UTR-wt or pMIR-AGGF1-3′-UTR-mut and 100 nM
of either a miRNA mimics negative control or a miR-27a mimics
(RiboBio). Forty-eight hours after transfection, cells were lysed in
passive lysis buffer (Promega,Madison,WI, USA) and activities of ﬁreﬂy
and renilla luciferase were measured with the dual-luciferase assay
system (Promega) with a GloMax luminometer (Promega).
2.8. Quantitative reverse-transcription PCR (qRT-PCR) analysis
Total RNA was isolated from cells using TRIzol reagent (TaKaRa
Biotech, Dalian, Liaoning, China) and quantiﬁed. Two micrograms of
RNA from each sample was treated with DNase I (Promega, Madison,
WI, USA) to remove contaminating genomic DNAand used for synthesis
of cDNA with M-MLV reverse transcriptase (Promega). The cDNA was
then analyzed by real-time quantitative PCR with FastStart SYBR
GreenMaster (Roche Applied Science,Mannheim, Germany). The prim-
er sequences used for qRT-PCRwere as follows:AGGF1, 5′-AATCCCTGAA
GTTGGTGTCA-3′ and 5′-GTTTTCGGCTGAAGAATCTG-3′; β-actin, 5′-
CATCGTCCACCGCAAATG-3′ and 5′-CACCTTCACCGTTCCAGTT-3′.
For themeasurement of the expression level ofmature hsa-miR-27a,
Bulge-loop™ miRNA qRT-PCR Primer Sets (RiboBio, Guangzhou,
Guangdong, China) were used. The U6 small RNA was used as an inter-
nal control.
Table 1
Immunohistochemical analysis of AGGF1 expression in urothelial carcinomas.
Negative− Weak + Strong +
Normal urothelium 0 0 7/7 (100%)a
Low-grade urothelial carcinoma 1/30 (3.3%) 5/30 (16.7%) 24/30 (80%)b
High-grade urothelial carcinoma 7/22 (31.8%) 11/22 (50%) 4/22 (18.2%)
a HGUCC versus normal urothelium, P=2.11 × 10−4 by a Fisher's exact test; Odds ratio
or OR could not be estimated because one of the variables is 0.
b HGUCC versus LGUCC, P = 1.40 × 10−5, OR (95% conﬁdence interval) = 0.056
(0.014–0.226) by a Pearson's Chi-square test.
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Cells were lysed in lysis buffer (20 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1% NP-40, proteinase inhibitor cocktail), and total
protein extracts were used for Western blot analysis as previously
described [13]. The primary antibodies used include a rabbit polyclonal
anti-AGGF1 antibody (1:2000, Proteintech, Wuhan, Hubei, China),
a rabbit polyclonal anti-HIF-1α antibody (1:2000, Proteintech) and
a mouse monoclonal anti-alpha tubulin (1:5000, Merck Millipore,
Darmstadt, Germany). The secondary antibodies were either a goat
anti-rabbit or a goat anti-mouse HRP-conjugated secondary antibody
(1:20,000, Sigma-Aldrich, Castle Hill, NSW, Australia). The images were
developed with the SuperSignal West Pico Chemiluminescent Substrate
(Pierce Chemical Co., Rockford, IL, USA) using a ChemiDoc XRS (Bio-Rad
Laboratories, Richmond, CA, USA), and analyzed with Gel-Pro analyzerFig. 2. AGGF1 protein levels are down-regulated under hypoxic conditions. Four different hum
(21% O2) or hypoxic conditions (3% O2) for 48 h and then used for measuring the protein levels
(A, B, C, D) Representative Western blot images. N, normoxia; H, hypoxia. Protein expression w
fold change. *, P b 0.05, **, P b 0.01. (E) Test of validity of the ELISA kit. The ELISA kit successfully
analysis for secreted AGGF1 in culture supernatants. J82 cells were cultured under either normo
secreted AGGF1 protein. (G) Hypoxia increased the secreted VEGFA protein (positive control).4. The data were presented as the fold change in the ratio of the intensity
of the AGGF1 band to that of the corresponding tubulin band.
2.10. Enzyme-linked immunosorbent assays (ELISA)
AGGF1 and VEGF-A levels in culture supernatants were analyzed
using a human AGGF1 ELISA kit (USCN Life Science, Wuhan, Hubei,
China) and a human VEGF-A ELISA kit (R&D Systems, Minneapolis, MN,
USA) according tomanufacturers' instructions. Standard curveswere cre-
ated by a series of concentrations of puriﬁed AGGF1 or VEGF-A using the
CurveExpert 1.3 software program.
2.11. Apoptosis assays
Transfected cells were treated with a hypoxia-mimetic, CoCl2, har-
vested and used for apoptosis assays using FC-500 ﬂow cytometry
(Beckman Coulter, Miami, FL, USA). Brieﬂy, cells were treated with
annexin V-FITC and propidium iodide (PI) from an Apoptosis Detection
Kit (KeyGEN, Nanjing, Jiangsu, China). Annexin V-FITC-positive cells
were counted as early apoptotic cells. Cells that were positive for both
annexin V-FITC and PI were counted as late apoptotic cells. Viable cells
were negative for both annexin V-FITC and PI [29].
2.12. Statistical analysis
The association analysis between the expression levels of AGGF1 and
different grades of urothelial carcinomas was performed using either aan cancer cell lines, J82, H1299, HeLa and HCT116, were cultured under either normoxic
of AGGF1 by Western blot analysis. β-Actin was used as an equal sample loading control.
as quantiﬁed by densitometric analysis. The ratio of AGGF1/β-actin is shown as the mean
detected puriﬁed AGGF1 protein in a concentration-dependent manner. (F)Western blot
xic or hypoxic conditions for 48 h and then culturemediawere collected formeasuring the
*, P b 0.05.
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software.
Other data were expressed as mean± standard deviation (SD). The
results were from at least three independent experiments. Statistical
analysis for comparison of means between two groups was carried out
with Student's t-tests using SPSS version 16.0 software.
A P-value of 0.05 or less was considered to be statistically
signiﬁcant.Fig. 3.Hypoxia-induced down-regulation of AGGF1was independent of transcriptional inhibitio
ysis under normoxic or hypoxic conditions. (B, C, D) ThemRNA levels ofHIF-1α, VEGF-A and AG
The ratios of HIF-1α/β-actin, VEGF-A/β-actin and AGGF1/β-actin were shown as the fold chang
normoxia or hypoxia. ***, P b 0.001. (F) AGGF1 protein stability assays. The degradation of theAG
treatment. J82 cells were cultured under the indicated conditions for 20 h, treated with cycloh
AGGF1 levels at different time points fromWestern blot images in (F). The ratio of AGGF1/tubu
were converted as relative values to that at time point 0. All experiments were performed in t3. Results
3.1. Signiﬁcant association of low expression of the AGGF1 proteinwith high
grade urothelial carcinoma
Angiogenesis-related factors have important clinical applications as
predictive markers of tumors [30–32]. As a newly-identiﬁed angiogenic
factor, the expression status of AGGF1 (GeneID: 55109) protein inn. (A) Protein levels of HIF-1α, AGGF1 andα-tubulinwere analyzed byWestern blot anal-
GF1were determined by real-time RT-PCR analysis under normoxic or hypoxic conditions.
e. (E) Real-time RT-PCR analysis for HIF1α, VEGFA and AGGF1 in J82 cells cultured under
GF1 proteinwas assessed after inhibition of denovoprotein synthesiswith cycloheximide
eximide for 6 to 24 h, and used for Western blot analysis of AGGF1. (G) Quantiﬁcation of
lin was plotted against time points. The ratio at time point 0 was set at 1.0 and other ratios
riplicate (n = 3).
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and neoplastic tissues from urothelial carcinomas of different histologi-
cal grades were used for evaluation of the expression level of the
AGGF1 protein using immunohistochemistry analysis. The expression
levels of the AGGF1 protein were classiﬁed into three tiers: no
expression (negative), weak expression (weak +) and strong
expression (strong +) as shown in Fig. 1A.
Normal urothelium showed strong expression of AGGF1 proteins
with strong circumferential membranous staining in all 7 samples
(100%; Fig. 1B, Table 1). Urothelial cancers of different grades exhibited
differential AGGF1 expression. Strong AGGF1 expression was detected
in 80% (24/30) of LGUCC and 18.2% (4/22) of HGUCC, respectively
(Fig. 1B, Table 1). Weak AGGF1 expression was detected in 0/7 normal
urothelium, 16.7% (5/30) LGUCC and 50% (11/22) HGUCC. No AGGF1
was detected in 0% (0/7) normal urothelium, 3.3% (1/30) LGUCC and
31.8% (7/22) HGUCC. The proportion of strong AGGF1 expression
cases was signiﬁcantly lower in the high-grade urothelial carcinoma
group than those in the low-grade urothelial carcinoma group (P =
1.40× 10−5, OR= 0.056) or than those in the normal urothelium tissue
group (P = 2.11 × 10−4). There was no difference between normal
urothelium and LGUCC in terms of AGGF1 protein expression (P =
0.57). Taken together, these data suggested that down-regulation of
AGGF1 protein expression was signiﬁcantly associated with a risk of
HGUCC.
3.2. Hypoxia down-regulates expression of AGGF1
Tumor hypoxia is more common in cases of high-grade superﬁcial
urothelial carcinoma because of increased proliferative activity of tumor
cells [33]. Thus, hypoxia may be responsible for the ﬁnding that AGGF1
protein expression was high in normal urothelium and low-grade
urothelial carcinomas, but low in high-grade urothelial bladder carcino-
mas. The key to test this hypothesis is to demonstrate that AGGF1 isFig. 4.MiR-27a regulates AGGF1 expression bybinding to a putative binding site in the 3′-UTRofA
the 3′-UTR of AGGF1mRNA, and the conserved sites in the human, chimpanzee, rhesus, mouse an
binding site or the related mutated site. (C) Data from luciferase assays in HEK293 cells. Repor
a miR-27a mimics or a negative control mimics into HEK293 cells. Cells were harvested 48 h
activities. Three independent experiments were performed. Error bars represent standard devdown-regulated in hypoxic conditions. Human bladder cancer cell line,
J82, was exposed to hypoxia (3% O2, 5% CO2, and 92% N2) for 48 h and
then used for measuring the expression level of AGGF1. Western blot
analysis showed that AGGF1 expression was decreased by N2-fold in
response to hypoxia as compared to normoxia (Fig. 2A).
To verify whether the decrease of AGGF1 expression in response
to hypoxia is cell-speciﬁc, we analyzed three other human cancer
cell lines, including human non-small cell lung carcinoma cell line
(H1299), human cervical cancer cell line (HeLa) and human colon carci-
noma cell line (HCT116). Hypoxia-induced down-regulation of AGGF1
was also observed in all three cell lines (Fig. 2B–D). All the results indi-
cated that AGGF1 expressionwas signiﬁcantly decreased in human can-
cer cells after exposure to hypoxia. It is interesting to note that hypoxia-
induced down-regulation of AGGF1 expression was more pronounced
in H1299 cells (N5-fold) than that in other cancer cells (Fig. 2B).
Since AGGF1 is known to be a secreted angiogenic growth factor
in human vascular endothelial cells, we next examined the levels of
AGGF1 secreted in the culture supernatant from cancer cells using
ELISA. To prevent detection of exogenous AGGF1 in FBS, cells were
cultured in DMEM without FBS. As shown in Fig. 2E, the ELISA kit can
detect the puriﬁed AGGF1 protein in a concentration-dependent
manner. However, ELISA failed to detect any AGGF1 protein in the
culture supernatant from J82 cells. Consistent with the data, Western
blot analysis also failed to detect expression of AGGF1 in the culture su-
pernatant under normoxia or hypoxic conditions (Fig. 2F). In contrast,
an increased level of VEGFA (positive control) was detected (Fig. 2G).
3.3. Down-regulation of AGGF1 protein under hypoxic conditionswas inde-
pendent of transcriptional inhibition
To further assess AGGF1 expression levels under hypoxic condi-
tions, we analyzed AGGF1 expression at different time-points during
hypoxia. We exposed HCT116 cells to hypoxia (3% O2, 5% CO2, andGGF1. (A)A schematic diagramshows thepredictedbinding sites ofmiR-27a/b andmiR-32 in
d rat. (B) A schematic diagram shows luciferase reporters containing the potential miR-27a
ters containing the wild-type or 4-bp mutant 3′-UTR of AGGF1 were co-transfected with
after transfection and luciferase activities were measured and normalized to the renilla
iation (SD). ***, P b 0.001.
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expression of HIF-1α, a marker for hypoxia, was induced at 2 h
after hypoxia. The magnitude of HIF-1α induction peaked at 6 h,
and then moderately decreased (Fig. 3A). By contrast, decreased
AGGF1 protein levels were observed at time points of 6 h, 24 h, and
48 h under hypoxic conditions (Fig. 3A). These results suggest thatFig. 5.MiR-27a inhibits expression of AGGF1 at the protein level. (A, E, I, M) The levels of miR
transfected with 100 nM of miR-27a mimics or miR-27a inhibitor. U6 small nuclear RNA was
the levels of the AGGF1 protein. Representative Western blot images are shown. α-Tubulin s
AGGF1mRNA levels after transfection with a miR-27a mimics or a negative control mimics. Th
protein expression. RepresentativeWestern blot images are shown.α-Tubulin serves as a loadin
after transfection with a miR-27a inhibitor or a negative control inhibitor. The results were nor
standard deviation (SD). *, P b 0.05; **, P b 0.01; ***, P b 0.001.expression of AGGF1 is independent of HIF-1α in HCT116 cells
under hypoxia.
To identify the possible mechanisms involved in the hypoxia-
induced change in AGGF1 expression, we examined mRNA expres-
sion of AGGF1 using real-time RT-PCR analysis. After cultured in
normoxic or hypoxic conditions, HCT116 cells were harvested to-27a were validated by semiquantitative end-point PCR analysis in HCT116 and J82 cells
used as an internal control. (B, C, J, K) Overexpression of miR-27a signiﬁcantly decreased
erves as a loading control. (D, L) Quantitative RT-PCR analysis was used to measure the
e results were normalized to β-actin. (F, G, N, O) Inhibition of miR-27a increased AGGF1
g control. (H, P) Quantitative RT-PCR analysiswasused tomeasure theAGGF1mRNA levels
malized to β-actin. Three independent experiments were performed. Error bars represent
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different treatment times. The results showed that hypoxia induced
increased mRNA expression of HIF-1α and VEGF-A in a time-
dependent manner. Increased expression of HIF-1α mRNA was de-
tected starting at the 24-h time point (Fig. 3B), while increased
HIF-1α protein was observed at 2 h (Fig. 3A) because of increased
protein stability [34]. Transcript levels of VEGF-A, a target of HIF1α,
increased at 2 h and reached a very high level at 24 h (Fig. 3C). How-
ever, AGGF1 mRNA levels did not change after exposure to hypoxic
conditions compared to normoxic conditions at all three time points
(Fig. 3D).
Similar ﬁndings were made in J82 bladder cancer cells (Fig. 3E).
Compared to normoxia, hypoxia induced signiﬁcantly increased expres-
sion of HIF1αmRNA and VEGFAmRNA, but not AGGF1mRNA. Together,
these data show that hypoxia does not affect the expression level of
AGGF1mRNA, instead, regulates AGGF1 protein expression, suggesting
that down-regulation of AGGF1 protein by hypoxia was independent
of transcriptional inhibition.
Down-regulation of AGGF1 protein by hypoxiamay also be caused by
changes in AGGF1 protein stability. To test this possibility, we exposed
J82 cells to hypoxia (1% O2) and then assessed degradation of the
AGGF1 protein using Western blot analysis after inhibition of de novo
protein synthesiswith cycloheximide treatment. Time-dependent degra-
dation of AGGF1 was observed both in normoxia and hypoxia. No signif-
icant difference of the AGGF1 half-life was detected between normoxia
and hypoxia (Fig. 3F and G). These results suggest that changes in
AGGF1 stability are not the major cause of down-regulation of AGGF1
by hypoxia.Fig. 6.MiR-27a was up-regulated under hypoxic conditions and inhibition ofmiR-27a can rescu
thematureMiR-27awere assessed inHCT116 and J82 cells after exposure to hypoxia. U6 small n
transfected with a miR-27a inhibitor and then exposed to hypoxic conditions. Western blot ana
the loading control.3.4. MicroRNA-27a down-regulates AGGF1 expression via translational
inhibition but not RNA degradation
Under hypoxic conditions, AGGF1 protein levels dropped without
changes in mRNA levels. Therefore, we hypothesized that miRNAs
were involved in hypoxia-induced down-regulation of AGGF1. The
downstream target genes of miRNAs can be predicted using multiple
algorithms [35]. We screened for miRNA binding sites in the 3′-UTR of
AGGF1 using three prediction algorithms: TargetScan 5.2, PicTar, and
miRanda. MiRNAs predicted to bind to the 3′-UTR of AGGF1 by all
three algorithms included miR-27a, miR-27b, and miR-32. The mature
sequences of the three miRNAs are shown in Fig. 4A. Interestingly, pre-
vious microarray-based expression proﬁling found that miR-27a was
induced in response to hypoxia [36], and hence we selected only miR-
27a for further study.
To verify that miR-27a regulates AGGF1 expression via the potential
binding site at the 3′-UTR of AGGF1, we constructed two luciferase
reporters: pMIR-AGGF1-3′-UTR-wt and pMIR-AGGF1-3′-UTR-mut
with a 4-bp mutation in the seed region of the putative binding site.
The wild-type AGGF1 3′-UTR or mutant 3′-UTR (Fig. 4B) was inserted
downstream of the ﬁreﬂy luciferase gene and transfected in HEK293
cells. For the wild-type reporter, overexpression of miR-27a mimics
(100nM) repressed the luciferase activity signiﬁcantly (P b 0.001) com-
pared to negative control miRNA mimics (Fig. 4C). In contrast, a
decrease in luciferase activity was not observed when miR-27a mimics
was co-transfected with the mutant reporter in HEK293 cells (Fig. 4C).
The results suggest that the predicted miR-27a binding site is responsi-
ble for repressing the expression of AGGF1.e hypoxia-induced down-regulation of AGGF1 in HCT116 and J82 cells. (A, B) The levels of
uclear RNAwas used as an internal control. ***, P b 0.001. (C, D)HCT116 and J82 cellswere
lysis was used to measure the expression level of the AGGF1 protein. β-Actin was used as
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to understand the precise mechanism, we transfected HCT116 with a
miR-27a mimics (100 nM) or a miR-27a inhibitor (100 nM) for 72 h
and then examined AGGF1mRNA and protein levels. Semiquantitative
end-point PCR analysis conﬁrmed the efﬁcacy of transfection by reveal-
ingmarkedly increased expression ofmaturemiR-27a after transfection
with themiR-27amimics (Fig. 5A). Compared to the controlmimics, the
miR-27amimics signiﬁcantly reduced AGGF1 protein expression by 2.5-
fold (Fig. 5B and C). Moreover, knocking down of miR-27a (Fig. 5E)
resulted in a consistent increase in AGGF1 protein expression by about
1.6 fold as quantitated by densitometric analyses (Fig. 5F and G).
However, there was no change in mRNA levels of AGGF1 regardless ofFig. 7. Correlation between up-regulation of miR-27a in high grade urothelial carcinomas and
urothelial carcinomas (UCC) and matched adjacent normal tissues were measured by qPCR a
grade tumors. **, P b 0.01. (B) The speciﬁcity of the polyclonal anti-AGGF1 antibodywas veriﬁe
of AGGF1 and from cells with knockdown of AGGF1 (siAGGF1-B, siAGGF1-C) or control siRNA
tissues were characterized using immunostaining analysis.overexpression or knockdown of miR-27a (Fig. 5D and H). Similar
results were obtained with J82 bladder cancer cells (Fig. 5I–P). Taken
together, these results indicate that miR-27a down-regulates AGGF1
expression through translational inhibition but not RNA degradation.
3.5. Up-regulation of miR-27a correlates with the down-regulation of AGGF1
protein levels under hypoxic conditions and in urothelial carcinomas
The status of miR-27a expression was tested in HCT116 cells after
exposure to hypoxia. The expression levels of mature miR-27a were
assessed using miR-27a speciﬁc stem-loop reverse transcription
primers and PCR ampliﬁcation primers. Semiquantitative end-pointdown-regulation of AGGF1. (A) The relative expression levels of miR-27a in four pairs of
nalysis. B35 and B76 were classiﬁed as high grade UCC, whereas B84 and B85 were low
d byWestern blot analysis with protein extracts from cells with orwithout overexpression
(siNC). (C-F) The levels of the AGGF1 protein in UCC tumor tissues and matched adjacent
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expression at the time-point of 6 h under hypoxic conditions (Fig. 6A,
P = 6.9 × 10−6). At 24 h, miR-27a expression was increased by up to
4-fold under hypoxic conditions compared to normoxic conditions
(Fig. 6A, P= 2.2 × 10−8). Similar results were obtained in J82 bladder
cancer cells (Fig. 6B, P= 7.2 × 10−5).
To correlate the miR-27a expression levels with the hypoxia-
induced decrease in AGGF1 expression, cells were transfected with
a miR-27a inhibitor or a control inhibitor and exposed to hypoxic
conditions. The hypoxia-induced decrease in AGGF1 expression
disappeared after transfection with the miR-27a inhibitor in HCT116
cells (Fig. 6C). Similar results were obtained in J82 bladder cancer cells
(Fig. 6D). Taken together, these data suggested that miR-27a was
induced by hypoxia and that the up-regulation of miR-27a expression
correlates with the down-regulation of AGGF1 protein level under hyp-
oxic conditions.
To further correlate the expression of miR-27a to that of AGGF1,
we have collected urothelial carcinoma tissue samples along with
normal adjacent urothelial tissue samples from 4 patients (B35,
B76, B84 and B85). B35 and B76 were classiﬁed as high grade
urothelial carcinomas, whereas B84 and B85 were low grade
urothelial carcinomas. Semiquantitative end-point RT-PCR analysis
showed that for B35 and B76, the expression levels of miR-27a in tu-
mors were signiﬁcantly higher than that in adjacent normal tissue
samples, whereas for B84 and B85, there was no signiﬁcant differ-
ence between the expression levels of miR-27a in tumors and in ad-
jacent normal tissue samples (Fig. 7A). These data are consistentFig. 8.Down-regulation of AGGF1 protein levels reduces hypoxia-induced apoptosis of HCT116 c
antibodies against annexin-V and PI under various culture conditions. AGGF1 expressionwas kn
(siNC), and exposed to hypoxiamimetic CoCl2 (1.5mM) for 16 h. (B) Changes in the proportion
were used for Western blot analysis to ensure knockdown of AGGF1 expression. **, P b 0.01.with the relative expression levels of the AGGF1 protein (Fig. 7B–F).
Immunohistochemical analysis with a speciﬁc anti-AGGF1 antibody
showed that the expression levels of the AGGF1 protein appeared to
be higher in B35 and B76 than those in B84 and B85 (Fig. 7B–F). These
results are consistent with the ﬁndings from the TMA studies described
above (Table 1).
3.6. Down-regulation of AGGF1 protein reduced hypoxia-induced apoptosis
in cancer cells
To assess the functional role of AGGF1 suppression under hypoxic
conditions, the proportion of apoptotic cells was examined under various
culture conditions. AGGF1 expressionwas knocked down in HCT116 cells
using two small interfering RNAs (siAGGF1-B and siAGGF1-C, Fig. 8C).
Cells were then exposed to hypoxic mimetic CoCl2 (1.5 mM) for 16 h
and used for apoptosis assays. The results of ﬂow cytometry analysis
showed that the proportion of apoptotic cells increased after CoCl2 treat-
ment (Fig. 8A). We calculated the total apoptosis ratio, including early
apoptotic cells and late apoptotic cells. Knock-down of AGGF1 expression
had little effect on apoptosis under normoxic conditions, but inhibited
apoptosis by 30% under hypoxic conditions (Fig. 8A and B). These results
suggested that down-regulation of AGGF1 protected cancer cells from
apoptosis only under hypoxic conditions.
In addition to mimicking hypoxia using CoCl2 treatment, we also
analyzed apoptosis after exposing either HCT116 or J82 cells to 1% O2.
As shown in Fig. 9, under normoxia, knockdown of AGGF1 expression
by two different siRNAs did not have any effect on apoptosis of bothells by treatmentwith CoCl2. (A) Apoptosiswas analyzed byﬂow cytometry analysis using
ocked down using two AGGF1 speciﬁc siRNAs (siAGGF1-B and siAGGF1-C) or control siRNA
of apoptotic cells are shown as fold changes. (C) Afterﬂow cytometry analysis, the samples
Fig. 9. Down-regulation of the AGGF1 protein reduces hypoxia-induced apoptosis of HCT116 and J82 cells by exposure to 1% O2. (A, C) HCT116 and J82 cells were transfected with two
AGGF1 speciﬁc siRNAs (siAGGF1-B and siAGGF1-C) or control siRNA (siNC), and exposed to hypoxia (1% O2). Apoptosis was analyzed by ﬂow cytometry analysis. (B, D) Changes in the
proportion of apoptotic cells are shown as the fold changes. Data are shown as mean ± SD (n = 3, **, P b 0.01. ***, P b 0.001).
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and J82 cells by about 10-fold and 5-fold, respectively, and knockdown
of AGGF1 expression inhibited hypoxia-induced apoptosis of HCT116
by 20%–40% and J82 cells by 50%–70% (Fig. 9). These results further
indicate that down-regulation of AGGF1 expression inhibits hypoxia-
induced hypoxia in cancer cells.
We also assessed the effect of overexpression of AGGF1 on apo-
ptosis. We found that overexpression of AGGF1 in HCT116 and J82
cells did not affect apoptosis under either normoxia or hypoxia
(Fig. 10).
4. Discussion
Increased angiogenesis is involved in the growth, metastasis,
and survival of various tumors, including urothelial carcinoma [37].Angiogenic factors such as VEGFA or HIF-1α (regulating expression
of VEGFA) were considered as potential biological markers for progres-
sion of bladder carcinomas to invasive tumors [38,39]. Therefore, in
this study, we tested the hypothesis that an increased expression
level of AGGF1, a newly identiﬁed angiogenic factor, might be
observed in high-grade urothelial carcinomas compared to low-grade
urothelial carcinomas or normal urothelial tissues. Surprisingly, oppo-
site, unexpected results were obtained. Strong positive expression of
AGGF1 was more frequently seen in normal urothelium samples and
low-grade urothelial bladder carcinomas while no or weak expression
of AGGF1 was dominant in high-grade urothelial bladder carcinomas
(Table 1). Statistical analysis identiﬁed signiﬁcant association between
down-regulation of AGGF1 and development of high-grade urothelial
bladder carcinomas (Table 1). Although the results were unexpected,
they nevertheless indicate that AGGF1 expression levels are associated
Fig. 10.Overexpression of AGGF1 protein had little effect on apopotosis under normoxia and hypoxia. HCT116 (A) and J82 (B) cells were transfectedwith an AGGF1 expression plasmid or
empty vector, cultured under the indicated conditions, and used for ﬂow cytometry analysis. Changes in the proportion of apoptotic cells are shown as the fold changes. Data are shown as
mean ± SD (n = 3, P N 0.05).
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a potentially useful marker of bladder cancer progression from low-
grade to high-grade tumors.
One limitation of the above ﬁnding is that the identiﬁed association
does not distinguish whether down-regulation of AGGF1 is the cause of
high-grade urothelial bladder carcinomas ormay be amere consequence.
The priori possibility is supported by the results that knockdown of
AGGF1 expression signiﬁcantly reduces apoptosis of tumor cells under
hypoxia (Figs. 8 and 9). Tumor growth creates areas of hypoxia because
of the limitation in oxygen diffusion provided by the host vasculature
[31]. Moreover, hypoxia has been reported to be more common in
high-grade urothelial carcinomas [33]. Western blot analysis showed
that hypoxia induced a signiﬁcant decrease inAGGF1protein levels in dif-
ferent human cancer cell lines (Figs. 2, 3). Reduced expression of AGGF1
under hypoxia may help survival of tumor cells (Figs. 8 and 9), possibly
resulting in development of high-grade urothelial bladder carcinomas.
The second limitation is that the sample size for the human tumor
study was small due to difﬁculties in collecting the matched tumors
and adjacent normal tissue samples. Therefore, the conclusion derived
from this analysis should be considered to be preliminary and future
studies with larger sample sizes are needed to validate the ﬁnding. The
third limitation is related to the data that down-regulation of AGGF1
reduced HCT116 and J82 apoptosis under hypoxia (Figs. 8 and 9), but
overexpression of AGGF1 in the same cells did not affect apoptosis
under hypoxia (Fig. 10). The reason underlying this discrepancy is
unknown. It is possible that the endogenous level of AGGF1 was high
and an additional increase of AGGF1 expression did not have further ef-
fect on apoptosis speciﬁcally under hypoxia.
The molecular mechanism by which hypoxia down-regulates
AGGF1 expression was investigated in great detail. The ﬁnding that
the mRNA level of AGGF1 did not change under hypoxia suggested
that the down-regulation was not at the transcriptional level and
miRNA may be involved. Bioinformatic analysis and follow-up molecu-
lar and cellular studies demonstrated that the hypoxia-induced
decrease of AGGF1 expression was dependent on miR-27a. First,
a miR-27a mimics signiﬁcantly decreased the expression level of
AGGF1 and inhibition of miR-27a increased AGGF1 protein expression
(Fig. 5). Second, miR-27a expression was up-regulated in high grade
urothelial carcinomas, which was accompanied by down-regulation of
AGGF1 (Fig. 7). Third, miR-27a showed up-regulation under hypoxic
conditions (Fig. 6). Fourth, the hypoxia-induced decrease of AGGF1
expression disappeared with knockdown of miR-27a expression
(Fig. 6). On the other hand, it is not clear whether miR-27a is the sole
microRNA involved in regulation of AGGF1 under hypoxia. It is a gener-
ally accepted rule that each miRNA regulates many target genes and
each gene (e.g. AGGF1) may be regulated by multiple miRNAs. Asdescribed earlier, bioinformatic analysis also identiﬁed two other
miRNAs, miR-27b and miR-32, that may also be involved in regulation
of AGGF1 expression. This possibility will be investigated in the future.
Our results suggest that down-regulation of AGGF1 expression
by hypoxia-induced miR-27a expression represents a new signaling net-
work for development of high-grade urothelial bladder carcinomas, how-
ever, itmaynot be the sole network. BesidesmiR-27a, othermiRNAs have
been found to be regulated by hypoxia [36]. Among them,miR-210 is the
most predominantly up-regulated miRNA under hypoxia. MiR-210 is
involved in tumor initiation, cell cycle regulation, mitochondrial metabo-
lism and angiogenesis by targeting E2F3, MYC antagonist (MNT), ephrin-
A3 (EFNA3) and iron-sulfur cluster scaffold protein (ISCU) [6,7,40–45].
MiR-21 induction by Akt2 during hypoxia promotes tumor resistance
via its targets, PDCD4 and Spry1 [46]. Additionally, p53-mediated repres-
sion ofmiR-17-92 expression likely has an important function in hypoxia-
induced apoptosis [47]. All of these data support the dominant role of
miRNAs in development of more invasive, high-grade tumors.
AGGF1 has been shown to be an angiogenic factor critical to
vasculogenesis (speciﬁcation of venous fate) and angiogenesis [15,17].
On the other hand, it has been puzzling to us that AGGF1 contains puta-
tive functional domains of the FHA domain and G-patch motif that are
more important for cellular functions in the nucleus [48,49]. The results
in this study suggest that AGGF1 may be a multi-functional protein with
roles in angiogenesis and other functions. This is supported by several
pieces of evidence. First, AGGF1 does not appear to play a role as an
angiogenic factor in high-grade urothelial bladder carcinomas because
increased angiogenesis, meaning increased AGGF1 expression, may
be expected in this type of tumors. Second, the expression pattern of
AGGF1 was not consistent with that of HIF1-a (Fig. 3), which induces
expression of angiogenic factors to increase angiogenesis under hypoxia.
Third, little AGGF1 appeared to be secreted by cancer cells. Finally,
down-regulation of AGGF1 played a protective role for tumor cells
under hypoxia, although the detailed molecular mechanism needs
future elucidation. Therefore, AGGF1 may turn out to be like FGF2 that
has important functional roles both inside and outside the nucleus.
Our initial immunohistochemical analysis of AGGF1 protein expres-
sion focused on urothelial carcinomas simply because of the availability
of tissue samples. Interestingly, we found that regulation of AGGF1
expression by hypoxia and bymiR-27a appeared to be universal in sev-
eral different cancer cell lines, e.g. the human bladder cancer cell line
(J82), human colon cancer cell line (HCT116), human cervical cancer
cell line (HeLa), human non-small cell lung carcinoma cell line
(H1299) and human embryonic kidney cell line (HEK293). Thus,
down-regulation of AGGF1 protein expression may be linked not only
to high-grade urothelial carcinoma, but also to other high-grade tumors.
Future studies are needed to verify this hypothesis.
724 Y. Xu et al. / Biochimica et Biophysica Acta 1842 (2014) 712–725In conclusion, the results in this study identify signiﬁcant association
between down-regulation of AGGF1 protein expression and risk of
development of high-grade urothelial carcinomas. We also report that
hypoxia-induced down-regulation of AGGF1 expression is dependent
on hypoxia-induced up-regulation of miR-27a, and may promote
survival of cancer cells.
Acknowledgments
Wethank Lei Li, NanWang, YufengYao, Qiulun Lv andothermembers
of Center for Human Genome Research for discussion and advice. This
work was supported by a National Basic Research (973) Program Grant
(2013CB0531101), the Hubei Province's Outstanding Medical Academic
Leader Program, the Specialized Research Fund for the Doctoral Program
of Higher Education from the Ministry of Education, the “Innovative
Development of New Drugs” Key Scientiﬁc Project (2011ZX09307-001-
09), a Grant from the State Key Laboratory of Freshwater Ecology and
Biotechnology (2011FB16), the Fundamental Research Funds for the
Central Universities (2010MS015), and the Key Academic Program
Leader Award of Wuhan City (200951830560).
References
[1] C.T. Taylor, E.P. Cummins, The role of nf-κb in hypoxia-induced gene expression,
Ann. N. Y. Acad. Sci. 1177 (2009) 178–184.
[2] E.M. Hammond, R.A. Freiberg, A.J. Giaccia, The roles of chk 1 and chk 2 in hypoxia
and reoxygenation, Cancer Lett. 238 (2006) 161–167.
[3] H. Okuyama, H. Endo, T. Akashika, K. Kato, M. Inoue, Downregulation of c-myc
protein levels contributes to cancer cell survival under dual deﬁciency of oxygen
and glucose, Cancer Res. 70 (2010) 10213–10223.
[4] L. Liu, M.C. Simon, Regulation of transcription and translation by hypoxia, Cancer
Biol. Ther. 3 (2004) 489–494.
[5] C. Camps, F.M. Buffa, S. Colella, J. Moore, C. Sotiriou, H. Sheldon, A.L. Harris, J.M.
Gleadle, J. Ragoussis, Hsa-mir-210 is induced by hypoxia and is an inde-
pendent prognostic factor in breast cancer, Clin. Cancer Res. 14 (2008)
1340–1348.
[6] S.Y. Chan, Y. Zhang, C. Hemann, C.E. Mahoney, J.L. Zweier, J. Loscalzo, Microrna-210
controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur
cluster assembly proteins iscu1/2, Cell Metab. 10 (2009) 273–284.
[7] J. Sarkar, D. Gou, P. Turaka, E. Viktorova, R. Ramchandran, J.U. Raj, Microrna-21
plays a role in hypoxia-mediated pulmonary artery smooth muscle cell prolif-
eration and migration, Am. J. Physiol. Lung Cell. Mol. Physiol. 299 (2010)
L861–L871.
[8] D.P. Bartel, C. Chen, Micromanagers of gene expression: the potentially widespread
inﬂuence of metazoan micrornas, Nat. Rev. Genet. 5 (2004) 396–400.
[9] L.P. Lim, N.C. Lau, P. Garrett-Engele, A. Grimson, J.M. Schelter, J. Castle, D.P.
Bartel, P.S. Linsley, J.M. Johnson, Microarray analysis shows that some
micrornas downregulate large numbers of target mRNAs, Nature 433 (2005)
769–773.
[10] B. Zhou, R. Ma, W. Si, S. Li, Y. Xu, X. Tu, Q. Wang, Microrna-503 targets fgf2 and
vegfa and inhibits tumor angiogenesis and growth, Cancer Lett. 333 (2013)
159–169.
[11] Y. Wei, A. Schober, C. Weber, Pathogenic arterial remodeling: the good and bad of
micrornas, Am. J. Physiol. Heart Circ. Physiol. 304 (2013) H1050–H1059.
[12] M.J. Bueno,M. Malumbres, Micrornas and the cell cycle, Biochim. Biophys. Acta 1812
(2011) 592–601.
[13] X. Tian, R. Kadaba, S. You, M. Liu, A.A. Timur, L. Yang, Q. Chen, P. Szafranski, S. Rao, L.
Wu, D.E. Housman, P.E. DiCorleto, D.J. Driscoll, J. Borrow, Q. Wang, Identiﬁcation of
an angiogenic factor that when mutated causes susceptibility to Klippel–Trenaunay
syndrome, Nature 427 (2004) 640–645.
[14] Y. Hu, L. Li, S.B. Seidelmann, A.A. Timur, P.H. Shen, D.J. Driscoll, Q.K. Wang,
Identiﬁcation of association of common aggf1 variants with susceptibility for
Klippel–Trenaunay syndrome using the structure association program, Ann. Hum.
Genet. 72 (2008) 636–643.
[15] D. Chen, L. Li, X. Tu, Z. Yin, Q. Wang, Functional characterization of Klippel–
Trenaunay syndrome gene aggf1 identiﬁes a novel angiogenic signaling pathway
for speciﬁcation of vein differentiation and angiogenesis during embryogenesis,
Hum. Mol. Genet. 22 (2013) 963–976.
[16] L. Li, D. Chen, J. Li, X. Wang, N. Wang, C. Xu, Q.K. Wang, Aggf1 acts at the top of the
genetic regulatory hierarchy in speciﬁcation of hemangioblasts in zebraﬁsh, Blood
123 (2014) 501–508.
[17] Q. Lu, Y. Yao, Y. Yao, S. Liu, Y. Huang, S. Lu, Y. Bai, B. Zhou, Y. Xu, L. Li, N. Wang, L.
Wang, J. Zhang, X. Cheng, G. Qin, W. Ma, C. Xu, X. Tu, Q. Wang, Angiogenic factor
aggf1 promotes therapeutic angiogenesis in a mouse limb ischemia model, PLoS
ONE 7 (2012) e46998.
[18] Z. Kirkali, T. Chan, M. Manoharan, F. Algaba, C. Busch, L. Cheng, L. Kiemeney, M.
Kriegmair, R. Montironi, W.M. Murphy, I.A. Sesterhenn, M. Tachibana, J. Weider,
Bladder cancer: epidemiology, staging and grading, and diagnosis, Urology 66
(2005) 4–34.[19] R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2013, CA Cancer J. Clin. 63
(2013) 11–30.
[20] F. Ayala De La Peña, K. Kanasaki, M. Kanasaki, N. Tangirala, G. Maeda, R. Kalluri, Loss
of p53 and acquisition of angiogenic microRNA proﬁle are insufﬁcient to facilitate
progression of bladder urothelial carcinoma in situ to invasive carcinoma, J. Biol.
Chem. 286 (2011) 20778–20787.
[21] I. Kausch, A. Böhle, Molecular aspects of bladder cancer: iii. Prognostic markers of
bladder cancer, Eur. Urol. 41 (2002) 15–29.
[22] B. Ehdaie, D. Theodorescu, Predicting tumor outcomes in urothelial bladder
carcinoma: turning pathways into clinical biomarkers of prognosis, Expert. Rev.
Anticancer. Ther. 8 (2008) 1103–1110.
[23] A. Mori, C. Moser, S.A. Lang, C. Hackl, E. Gottfried, M. Kreutz, H.J. Schlitt, E.K. Geissler,
O. Stoeltzing, Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted
by interleukin-1β signaling and hypoxia-inducible factor-1α, Mol. Cancer Res. 7
(2009) 1390–1398.
[24] S. Pennacchietti, P. Michieli, M. Galluzzo, M. Mazzone, S. Giordano, P.M. Comoglio,
Hypoxia promotes invasive growth by transcriptional activation of the met
protooncogene, Cancer Cell 3 (2003) 347–361.
[25] S. Lee, T.T. Chen, C.L. Barber, M.C. Jordan, J. Murdock, S. Desai, N. Ferrara, A. Nagy, K.P.
Roos, M.L. Iruela-Arispe, Autocrine vegf signaling is required for vascular
homeostasis, Cell 130 (2007) 691–703.
[26] A. Grimson, K.K.H. Farh, W.K. Johnston, P. Garrett-Engele, L.P. Lim, D.P. Bartel,
MicroRNA targeting speciﬁcity in mammals: determinants beyond seed pairing,
Mol. Cell 27 (2007) 91–105.
[27] M. Rehmsmeier, P. Steffen, M. Höchsmann, R. Giegerich, Fast and effective
prediction of microRNA/target duplexes, RNA 10 (2004) 1507–1517.
[28] D. Betel, M. Wilson, A. Gabow, D.S. Marks, C. Sander, The microRNA. Org resource:
targets and expression, Nucleic Acids Res. 36 (2008) D149–D153.
[29] Y. Shounan, X. Feng, P.J. O'Connell, Apoptosis detection by annexin v binding:
a novel method for the quantitation of cell-mediated cytotoxicity, J. Immunol.
Methods 217 (1998) 61–70.
[30] M. Sund,M. Zeisberg, R. Kalluri, Endogenous stimulators and inhibitors of angiogenesis
in gastrointestinal cancers: basic science to clinical application, Gastroenterology
129 (2005) 2076–2091.
[31] I. Zlobec, R. Steele, C.C. Compton, Vegf as a predictive marker of rectal tumor
response to preoperative radiotherapy, Cancer 104 (2005) 2517–2521.
[32] E. Mylona, P. Alexandrou, I. Giannopoulou, G. Liapis, M. Soﬁa, A. Keramopoulos, L.
Nakopoulou, The prognostic value of vascular endothelial growth factors (vegfs)-a
and -b and their receptor, vegfr-1, in invasive breast carcinoma, Gynecol. Oncol.
104 (2007) 557–563.
[33] V.E. Theodoropoulos, A.C. Lazaris, I. Kastriotis, C. Spiliadi, G.E. Theodoropoulos, V.
Tsoukala, E. Patsouris, F. Sofras, Evaluation of hypoxia-inducible factor 1α
overexpression as a predictor of tumour recurrence and progression in superﬁcial
urothelial bladder carcinoma, BJU Int. 95 (2005) 425–431.
[34] P. Jaakkola, D.R. Mole, Y. Tian, M.I. Wilson, J. Gielbert, S.J. Gaskell, A.V. Kriegsheim,
H.F. Hebestreit, M. Mukherji, C.J. Schoﬁeld, Targeting of hif-alpha to the von
Hippel–Lindau ubiquitylation complex by o2-regulated prolyl hydroxylation, Sci.
Signal. 292 (2001) 468.
[35] D.E. Kuhn, M.M. Martin, D.S. Feldman, A.V. Terry Jr., G.J. Nuovo, T.S. Elton,
Experimental validation of miRNA targets, Methods 44 (2008) 47–54.
[36] R. Kulshreshtha, M. Ferracin, S.E. Wojcik, R. Garzon, H. Alder, F.J. Agosto-Perez, R.
Davuluri, C. Liu, C.M. Croce, M. Negrini, G.A. Calin, M. Ivan, A microRNA signature
of hypoxia, Mol. Cell. Biol. 27 (2007) 1859–1867.
[37] J. Folkman, Y. Shing, Angiogenesis, J. Biol. Chem. 267 (1992) 10931–10934.
[38] G. Pignot, I. Bieche, S. Vacher, C. Güet, A. Vieillefond, B. Debré, R. Lidereau, D.
Amsellem-Ouazana, Large-scale real-time reverse transcription-pcr approach of
angiogenic pathways in human transitional cell carcinoma of the bladder: identiﬁ-
cation of vegfa as a major independent prognostic marker, Eur. Urol. 56 (2009)
678–689.
[39] V.E. Theodoropoulos, A.C. Lazaris, F. Sofras, I. Gerzelis, V. Tsoukala, I. Ghikonti, K.
Manikas, I. Kastriotis, Hypoxia-inducible factor 1α expression correlates with
angiogenesis and unfavorable prognosis in bladder cancer, Eur. Urol. 46 (2004)
200–208.
[40] W. Yang, T. Sun, J. Cao, F. Liu, Y. Tian,W. Zhu, Downregulation of mir-210 expression
inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic
human hepatoma cells in vitro, Exp. Cell Res. 318 (2012) 944–954.
[41] X. Huang, L. Ding, K.L. Bennewith, R.T. Tong, S.M. Welford, K.K. Ang, M. Story, Q. Le,
A.J. Giaccia, Hypoxia-inducible mir-210 regulates normoxic gene expression
involved in tumor initiation, Mol. Cell 35 (2009) 856–867.
[42] A. Giannakakis, R. Sandaltzopoulos, J. Greshock, S. Liang, J. Huang, K. Hasegawa, C. Li,
A. O'Brien-Jenkins, D. Katsaros, B.L. Weber, Mir-210 links hypoxia with cell cycle
regulation and is deleted in human epithelial ovarian cancer, Cancer Biol. Ther. 7
(2008) 255–264.
[43] Z. Zhang, H. Sun, H. Dai, R. Walsh, M. Imakura, J. Schelter, J. Burchard, X. Dai, A.N.
Chang, R.L. Diaz, J.R. Marszalek, S.R. Bartz, M. Carleton, M.A. Cleary, P.S. Linsley, C.
Grandori, MicroRNA mir-210 modulates cellular response to hypoxia through the
myc antagonist mnt, Cell Cycle 8 (2009) 2756–2768.
[44] P. Fasanaro, Y. D'Alessandra, V. Di Stefano, R. Melchionna, S. Romani, G. Pompilio,
M.C. Capogrossi, F. Martelli, MicroRNA-210 modulates endothelial cell response to
hypoxia and inhibits the receptor tyrosine kinase ligand ephrin-a3, J. Biol. Chem.
283 (2008) 15878–15883.
[45] D. Lee, R. Romero, J. Kim, A.L. Tarca, D. Montenegro, B.L. Pineles, E. Kim, J. Lee, S.Y. Kim,
S. Draghici, P. Mittal, J.P. Kusanovic, T. Chaiworapongsa, S.S. Hassan, C.J. Kim, Mir-210
targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines:
siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia
and small-for-gestational-age pregnancies, Am. J. Pathol. 179 (2011) 590–602.
725Y. Xu et al. / Biochimica et Biophysica Acta 1842 (2014) 712–725[46] C. Polytarchou, D. Iliopoulos, M. Hatziapostolou, F. Kottakis, I. Maroulakou, K. Struhl,
P.N. Tsichlis, Akt2 regulates all akt isoforms and promotes resistance to hypoxia
through induction of mir-21 upon oxygen deprivation, Cancer Res. 71 (2011)
4720–4731.
[47] H. Yan, G. Xue, Q. Mei, Y. Wang, F. Ding, M. Liu, M. Lu, Y. Tang, H. Yu, S. Sun,
Repression of the mir-17-92 cluster by p53 has an important function in
hypoxia-induced apoptosis, EMBO J. 28 (2009) 2719–2732.[48] A. Mahajan, C. Yuan, H. Lee, E.S.W. Chen, P. Wu, M. Tsai, Structure and function of
the phosphothreonine-speciﬁc fha domain, Sci. Signal. 1 (2008) e12.
[49] L. Aravind, E.V. Koonin, G-patch: a new conserved domain in eukaryotic
RNA-processing proteins and type d retroviral polyproteins, Trends Biochem. Sci.
24 (1999) 342–344.
